Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
The recent development of immunotherapy represents a significant breakthrough in cancer therapy.Several immunotherapies provide robust Baby Care efficacy gains in a wide variety of cancers.However, in some patients the immune checkpoint blockade remains ineffective due to poor therapeutic response and tumor relapse.An improved understanding of the